Research advance on transfusion-related immunomodulation.
- Author:
Xin-Fang ZHU
1
;
Rong XIA
Author Information
1. Department of Blood Transfution, Fudan University Huashan Hospital, Shanghai 200040, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Humans;
Immunomodulation;
Immunosuppression;
Platelet Transfusion;
adverse effects;
Transfusion Reaction
- From:
Journal of Experimental Hematology
2010;18(1):268-272
- CountryChina
- Language:Chinese
-
Abstract:
As allogeneic blood transfusion plays a role in clinical treatment effects, it also produces a number of immune-related side effects, such as the increased rate of postoperative infection, the rising relapse rate of malignant resection and so on. All those factors, such as CD200 surface molecule of allogeneic mononuclear cells, interleukin, sHLA and sFasL which are detached from the leukocyte surface during the period of storage, and serum bioactive molecules related to a certain degree with the occurrence of transfusion-related immunomodulation (TRIM). The clinical controlled trials, laboratory researches and animal models demonstrated that cloning deletion, induction of anergy and immune suppression are the three major mechanisms of TRIM. In this article, the research advances on mechanism of TRIM and the mediators inducing TRIM are reviewed.
